Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
25 juil. 2022 16h05 HE
|
Otonomy, Inc.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
09 mai 2022 16h04 HE
|
Otonomy, Inc.
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
02 mai 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
15 mars 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28 févr. 2022 16h27 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy to Participate in Two Upcoming Investor Conferences
28 févr. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
16 nov. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
26 janv. 2016 07h05 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
12 janv. 2016 09h27 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Present at J.P. Morgan Healthcare Conference
08 janv. 2016 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...